ImmunityBio

IBRX

Market cap $2.76B

Overview Fund Activity

2.92 USD

+0.11

3.91%

At close Updated Sep 17, 12:11 PM EDT

1 day

3.91%

5 days

13.18%

1 month

20.16%

3 months

2.82%

6 months

0.34%

Year to date

13.62%

1 year

-12.05%

5 years

-64.95%

10 years

-84.57%

About: ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.

Employees: 685

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

176% more repeat investments, than reductions

Existing positions increased: 102 | Existing positions reduced: 37

122% more first-time investments, than exits

New positions opened: 60 | Existing positions closed: 27

37% more capital invested

Capital invested by funds: $239M [Q1] → $328M (+$88.3M) [Q2]

14% more funds holding

Funds holding: 208 [Q1] → 238 (+30) [Q2]

4.73% more ownership

Funds ownership: 9.32% [Q1] → 14.05% (+4.73%) [Q2]

3% less call options, than puts

Call options by funds: $11.9M | Put options by funds: $12.2M

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$8

174% upside

Avg. target

$16

448% upside

High target

$24

722% upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Andres Y. Maldonado	$8	Buy Reiterated	10 Sep 2025
D. Boral Capital Jason Kolbert	$24	Buy Maintained	8 Sep 2025

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about IBRX published over the past 30 days

ImmunityBio: Still Too Early To Judge Anktiva, Although Clock Is Ticking

I maintain a Hold rating on ImmunityBio as Anktiva shows strong NMIBC data but the commercial uptake remains slow and uncertain. IBRX's Q2 revenues rose to $26.4M, but accumulated losses and lack of forward guidance raise valuation concerns despite a large market opportunity. FDA setbacks and slow Anktiva sales growth temper enthusiasm, with expansion into new indications still at an early and risky stage.

ImmunityBio: Still Too Early To Judge Anktiva, Although Clock Is Ticking

ImmunityBio's ANKTIVA® Reverses Lymphopenia and Extends Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Resistant to Checkpoint Therapy

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced new paradigm changing findings from the Phase 2 QUILT-3.055 study, demonstrating ANKTIVA® (nogapendekin alfa inbakicept-pmln) reverses lymphopenia (low natural killer and T cells) in patients with checkpoint inhibitor-resistant advanced non-small cell lung cancer (NSCLC), with this reversal resulting in significant prolonged median overall survival (mOS). The results were pre.

ImmunityBio's ANKTIVA® Reverses Lymphopenia and Extends Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Resistant to Checkpoint Therapy

Initial Data Shows 100% Disease Control in 5 Out of 5 Patients With Recurrent Glioblastoma With Two Patients in Near Complete Response Treated With ImmunityBio's ANKTIVA®, NK Cell Therapy Plus Optune Gio® Device

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced early findings from the first five recurrent glioblastoma patients treated with its investigational immune-boosting regimen including ANKTIVA® (nogapendekin alfa inbakicept-pmln) in this pilot study (NCT06061809). All five patients achieved 100% disease control with the regimen that combines ANKTIVA, an IL-15 agonist being studied for its ability to enhance natural killer (NK.

Initial Data Shows 100% Disease Control in 5 Out of 5 Patients With Recurrent Glioblastoma With Two Patients in Near Complete Response Treated With ImmunityBio's ANKTIVA®, NK Cell Therapy Plus Optune Gio® Device

ImmunityBio Announces Phase 2 Study of ANKTIVA® in Patients with Long COVID

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the opening of a new Phase 2 study to assess the BioShield™ platform, anchored by ANKTIVA® (nogapendekin alfa inbakicept-pmln), in patients with long COVID. An estimated one in five Americans with a previous COVID-19 infection has long COVID, which is comprised of a broad range of symptoms that can substantially impact a patient's quality of life. Long COVID remains a signifi.

ImmunityBio Announces Phase 2 Study of ANKTIVA® in Patients with Long COVID

ImmunityBio Reports Complete Responses in Non-Hodgkin Waldenstrom Lymphoma Patients with Chemotherapy-Free, First-In-Class CD19 CAR-NK Immunotherapy

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio (NASDAQ: IBRX), a leading immunotherapy company, announced today early findings from its QUILT-106 Phase I trial, showing highly promising complete responses in the first two patients treated to date with late-stage Waldenstrom macroglobulinemia (WM)—a type of non-Hodgkins lymphoma (NHL)—using its CD19 CAR-NK (CD19 t-haNK) natural killer cell therapy. QUILT-106 (NCT06334991) is a first-in-human trial evaluating the safety and preliminary efficac.

ImmunityBio Reports Complete Responses in Non-Hodgkin Waldenstrom Lymphoma Patients with Chemotherapy-Free, First-In-Class CD19 CAR-NK Immunotherapy

ImmunityBio Announces Houston's Michael E. DeBakey VA Medical Center Is Among the First VA Hospitals to Administer ANKTIVA® to Bladder Cancer Patients

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the Michael E. DeBakey Department of Veterans Affairs (VA) Medical Center in Houston recently became the first VA hospital in the Houston region and one of the first in the U.S. to provide treatment with ANKTIVA® (nogapendekin alfa inbakicept-pmln) to a veteran with bladder cancer. ANKTIVA, the first of its kind immune-boosting, lymphocyte stimulating agent, is approved by th.

ImmunityBio Announces Houston's Michael E. DeBakey VA Medical Center Is Among the First VA Hospitals to Administer ANKTIVA® to Bladder Cancer Patients

The Motley Fool

IBRX Sales Soar 2,540%

ImmunityBio (IBRX -0.21%), a commercial-stage biotechnology company, released its second-quarter results on August 5, 2025. The main headline: revenue (GAAP) jumped to $26.4 million, soundly beating analyst GAAP revenue estimates of $23.15 million, as commercial sales of the immunotherapy ANKTIVA accelerated.

IBRX Sales Soar 2,540%

Zacks Investment Research

ImmunityBio (IBRX) Reports Q2 Loss, Tops Revenue Estimates

ImmunityBio (IBRX) came out with a quarterly loss of $0.1 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.2 per share a year ago.

ImmunityBio (IBRX) Reports Q2 Loss, Tops Revenue Estimates

ImmunityBio Reports Q2 Earnings Release Reflecting 60% Increase in Revenue in Q2 2025, With Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-code

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced its financial results for the fiscal quarter and six months ended June 30, 2025. In the second quarter of 2025, ImmunityBio reported $26.4 million in revenue, representing a 60% increase from $16.5 million in the first quarter of 2025. This growth reflects continued commercial traction of ANKTIVA in combination with BCG in BCG-unresponsive NMIBC with carcinoma in situ (CIS) w.

ImmunityBio Reports Q2 Earnings Release Reflecting 60% Increase in Revenue in Q2 2025, With Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-code

ImmunityBio, Inc. Announces Execution of $80 Million Equity Financing from Multiple Institutional Investors

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that it has executed financing to provide further working capital and support its ongoing business operations. The Company entered into a securities purchase agreement for a registered direct offering with two institutional investors, providing for the issuance of common stock of ImmunityBio as well as warrants for the purchase of additional shares of common stock of Immunity.

ImmunityBio, Inc. Announces Execution of $80 Million Equity Financing from Multiple Institutional Investors

See News Rankings

Charts implemented using Lightweight Charts™